EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 EPS of ($0.64), $0.14 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $11.58 million versus the consensus estimate of $10.61 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.